Lena Nanoceutics Ltd., Institute of Pharmaceutical Innovation, Bradford BD7 1DP, UK.
Int J Pharm. 2011 Aug 30;415(1-2):307-14. doi: 10.1016/j.ijpharm.2011.06.002. Epub 2011 Jun 12.
A critical problem associated with poorly soluble drugs is low and variable bioavailability derived from slow dissolution and erratic absorption. The preparation of nano-formulations has been identified as an approach to enhance the rate and extent of drug absorption for compounds demonstrating limited aqueous solubility. A new technology for the production of nano-particles using high speed, high efficiency processes that can rapidly generate nano-particles with rapid dissolution rate has been developed. Size reduction of a low melting ductile model compound was achieved in periods less than 1h. Particle size reduction of ibuprofen using this methodology resulted in production of crystalline particles with average diameter of approximately 270nm. Physical stability studies showed that the nano-suspension remained homogeneous with slight increases in mean particle size, when stored at room temperature and under refrigerated storage conditions 2-8°C for up to 2 days. Powder containing crystalline drug was prepared by spray-drying ibuprofen nano-suspensions with mannitol dissolved in the aqueous phase. Dissolution studies showed similar release rates for the nano-suspension and powder which were markedly improved compared to a commercially available drug product. Ibuprofen nano-particles could be produced rapidly with smaller sizes achieved at higher suspension concentrations. Particles produced in water with stabilisers demonstrated greatest physical stability, whilst rapid dissolution was observed for the nano-particles isolated in powder form.
与难溶性药物相关的一个关键问题是,由于溶解缓慢和吸收不稳定,导致生物利用度低且变化大。制剂纳米化已被确定为提高具有有限水溶解度的化合物的药物吸收速度和程度的一种方法。已经开发出一种使用高速、高效率工艺生产纳米颗粒的新技术,该技术可以快速生成具有快速溶解速率的纳米颗粒。在不到 1 小时的时间内,实现了低熔点韧性模型化合物的粒径减小。使用该方法对布洛芬进行粒径减小,得到了平均直径约为 270nm 的结晶颗粒。物理稳定性研究表明,纳米混悬剂在室温下和 2-8°C 冷藏条件下储存长达 2 天时保持均匀,平均粒径略有增加。通过将布洛芬纳米混悬液与溶解在水相中的甘露醇喷雾干燥,制备含有结晶药物的粉末。溶出研究表明,纳米混悬剂和粉末的释放速率相似,与市售药物产品相比,释放速率明显提高。布洛芬纳米颗粒可以快速生产,并且在较高的悬浮浓度下可以实现更小的粒径。在含有稳定剂的水中生产的颗粒表现出最大的物理稳定性,而在粉末形式中分离出的纳米颗粒则表现出快速溶解。